Anping Guo

Mrs. Anping Guo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HTHaizhu Tan
Haizhu Tan
HCHongyu Chen
Hongyu Chen
ZWZhenmao Wang
Zhenmao Wang
MHMingguang He
Mingguang He
CWChiyu Wei
Chiyu Wei
AGAnping Guo
Anping Guo
Background: Facial biometric data, while valuable for clinical applications, poses substantial privacy and security risks. Objective: This paper aims to address the privacy and security concerns related to facial biometric data and support auxiliary diagnoses, in pursuit of which we developed Digital FaceDefender, an artificial intelligence–driven privacy safeguard solution. Methods: We constructed a diverse set of digitally synthesized Asian face avatars representing both sexes, spanning ages 5 to 85 years in 10-year increments, using 70,000 facial images and 13,061 Asian face images. Landmark data were separately extracted from both patient and avatar images. Affine transformations ensured spatial alignment, followed by color correction and Gaussian blur to enhance fusion quality. For auxiliary diagnosis, we established 95% CIs for pixel distances within the eye region on a cohort of 1163 individuals, serving as diagnostic benchmarks. Reidentification risk was assessed using the ArcFace model, applied to 2500 images reconstructed via Detailed Expression Capture and Animation (DECA). Finally, Cohen Kappa analyses (n=114) was applied to assess agreement between diagnostic benchmarks and ophthalmologists’ evaluations. Results: Compared to the DM method, Digital FaceDefender significantly reduced facial similarity scores (FDface vs raw images: 0.31; FLAME_FDface vs raw images: 0.09) and achieved zero Rank-1 accuracy in Pose #2-#3 and Pose #2-#5, with near-zero accuracy in Pose #4 (0.02) and Pose #5 (0.04), confirming lower reidentification risk. Cohen Kappa analysis demonstrated moderate agreement between our benchmarks and ophthalmologists’ assessments for the left eye (κ=0.37) and right eye (κ=0.45; both P <.001), validating diagnostic reliability of the benchmarks. Furthermore, the user-friendly Digital FaceDefender platform has been established and is readily accessible for use. Conclusions: In summary, Digital FaceDefender effectively balances privacy protection and diagnostic use.

11 February 2026 in Biomedical Chromatography
Verified
Journal Article
Open access
YYYuan Yao
Yuan Yao
GHGuang‐Yao Huang
Guang‐Yao Huang
TWTing‐Ting Wu
Ting‐Ting Wu
TTTing‐Fei Tan
Ting‐Fei Tan
FHFeng‐Mei Hu
Feng‐Mei Hu
JWJunping Wang
Junping Wang
Monoclonal antibody (mAb) therapies have revolutionized cancer treatment, significantly improving patient outcomes. However, the pharmacokinetics (PK) and pharmacodynamics (PD) of mAbs exhibit considerable variability due to nonlinear kinetics and individual differences, highlighting the need for therapeutic drug monitoring (TDM). Therefore, this study aimed to develop and validate a reliable LC–MS/MS method for the simultaneous quantification of bevacizumab, trastuzumab, rituximab, and pertuzumab in human serum and evaluate its clinical applicability. Characteristic peptides were identified using Skyline. Serum samples underwent Protein G purification and trypsin digestion. Separation used a C18 column with 0.1% FA and acetonitrile, and detection employed multiple reaction monitoring with cadonilimab as the internal standard. The method demonstrated excellent linearity (1–200 μg/mL), precision (CV < 8.9%), and accuracy (±9.8%). With a runtime of 12 min, the validated method requires only 10 μL of serum per sample and meets international validation standards, supporting the clinical monitoring of these therapies. A robust, cost‐effective, and high‐throughput LC–MS/MS method was successfully developed for the simultaneous quantification of four therapeutic mAbs. The method significantly reduces sample volume and analysis time while maintaining high accuracy and reproducibility, making it well‐suited for routine TDM and broader clinical applications.

1 April 2026 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
XCXiaoyu Cheng
Xiaoyu Cheng
AGAnping Guo
Anping Guo
FWFengmei Wang
Fengmei Wang
Lymphatic cyst with infection is caused by interruption of lymphatic vessels during para-aortic lymphnode dissection in patients with gynecological malignancies. It is generally considered that the infection is caused by bacteria invading through the lower limb and perineal wound, but the pathogenic factors of most lymphatic cysts are not clear. Our literature search revealed no previously reported cases similar to ours, in which a lymphatic cyst infection resulted from a co-infection with Streptococcus mitis/oralis (S. mitis/oralis) and Klebsiella pneumoniae (K. pneumoniae). A woman of 61 years of age, was diagnosed in endometrial cancer, carcinosarcoma FIGO grade 3, stage IIIC of the FIGO system. During the third postoperative pelvic replacement and drainage procedure, the patient developed a fever with a peak temperature of 39.2°C on the second day after the removal of the drainage tube. Empiric broad-spectrum antibiotics were started upon hospital readmission, but the patient showed poor response to therapy, with persistent and recurrent lower abdominal tenderness, raising concern for ongoing intra-abdominal or pelvic infection. As a result, it is important to identify pathogenic bacteria associated with lymphatic cyst infections and determine antimicrobial regimens. We further investigated the pathogenicity and antibiotic resistance of S. mitis/oralis, formulated an appropriate anti-infective treatment strategies. Consequently, the patient recovered and was discharged.

4 December 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HTHaizhu Tan
Haizhu Tan
HCHongyu Chen
Hongyu Chen
ZWZhenmao Wang
Zhenmao Wang
MHMingguang He
Mingguang He
CWChiyu Wei
Chiyu Wei
AGAnping Guo
Anping Guo